Brickell Biotech Inc., of Miami, secured the exclusive worldwide rights to a series of retinoic acid-related orphan nuclear receptor gamma (RORy) inhibitors from Orca Pharmaceuticals Inc., of Oxford, U.K., and New York University. Under the terms of the agreement, Brickell will assume the responsibility for the continued research and development of those RORy inhibitors, initially targeting the topical treatment of psoriasis.